Neurorehabilitation News

Bypassing the blood-brain barrier remains an obstacle for novel therapeutics. Healio spoke to Thomas Chen, MD, PhD, founder and CEO of NeOnc, to find out how a novel nasal spray formulation to treat brain cancer overcomes these challenges.

The FDA has approved Crexont extended-release capsules for the treatment of Parkinson’s disease, according to the manufacturer.

PHILADELPHIA — Treatment with lecanemab slowed the progression of a potential novel Alzheimer’s disease-related biomarker by 44% over 18 months compared with placebo, with the biomarker itself most correlating with tauopathy, data show.

PHILADELPHIA — Among men who played American football, researchers found that exposure to the sport at a younger age was strongly associated with worse cognitive performance and resilience, particularly in those who lived to at least 60 years.

PHILADELPHIA — Individuals who consumed about two weekly servings of processed red meat had a 14% higher risk for dementia, as well as accelerated cognitive aging, vs. those who ate less than three servings a month, according to research.

PHILADELPHIA — Exposure to wildfire smoke and fine particulates was associated with increased risk of a dementia diagnosis in a cohort of older adults, data show.

NEW YORK — Paying attention to one’s lifestyle is a cornerstone to maintaining and improving both physical and mental health, according to the new president of the American Psychiatric Association.

Annovis Bio Inc. has secured a U.S. patent for methods of treating acute traumatic brain injuries with its lead drug candidate, an oral, small molecule neurotoxic protein inhibitor.

Published data showed psychological symptoms following sport-related concussions are common in high school athletes and may delay their recovery.

Improvements in “on” time were observed as early as day 3 after treatment initiation with an investigational subcutaneous combination therapy for Parkinson’s disease, which also led to significant improvement by day 7, data show.